First Trade Date for ImClone Systems Inc.
| Company Name | First Trade Date (yyyy-mm-dd) |
| ImClone Systems Inc. | 1991-11-19 |
| Company Name | Symbol |
| ImClone Systems Inc. | IMCL |
| History and Business of Company (this information may include date of incorporation) | |
|
ImClone Systems Inc.'s (IMCL) lead product candidate, IMC-C225, is a therapeutic monoclonal antibody that inhibits stimulation of a receptor for growth factors upon which certain solid tumors depend in order to grow. IMC-C225 has been shown in several Phase I/II trials to have an acceptable safety profile, to be well tolerated and, when administered with either radiation therapy or chemotherapy, to enhance tumor reduction. IMC-C225 is in potential registration studies for treating head and neck cancer. Upon the receipt of regulatory approval, IMCL intends to market IMC-C225 in the United States and Canada. IMCL will rely on its development and marketing partner, Merck KGaA, to market IMC-C225 outside the United States and Canada and to pay the company a royalty on all such sales. IMCL is responsible for the manufacture and supply of IMC-C225 for all clinical trials and eventual commercial sales. IMCL's next most advanced product candidate, BEC2, is a cancer vaccine. In partnership with Merck KGaA, IMCL is testing BEC2 for preventing recurrence or progression of small-cell lung cancer in a Phase III pivotal trial. Upon receipt of regulatory approval, IMCL intends to co-promote BEC2 with Merck KGaA in North America. Merck KGaA will be responsible for developing and marketing BEC2 outside North America and will be obligated to pay IMCL royalties on all such sales. In addition, IMCL intends to be the worldwide manufacturer of BEC2. IMCL is also developing inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. IMCL has identified IMC-1C11 as its lead clinical candidate for angiogenesis inhibition. IMC-1C11 is an antibody that binds selectively and with high affinity to KDR, a principal Vascular Endothelial Growth Factor (VEGF) receptor, thereby inhibiting angiogenesis. IMCL commenced clinical trials of IMC-1C11 in March 2000. The company is also developing a fully human monoclonal antibody candidate for angiogenesis inhibition. In addition to the development of its lead product candidates, IMCL continues to conduct research, both independently and in collaboration with academic and corporate partners, in a number of areas related to its core focus of growth factor inhibitors, therapeutic cancer vaccines and anti-angiogenesis inhibitors. IMCL has also developed diagnostic products and vaccines for certain infectious diseases, and it has licensed the rights to these products and vaccines to corporate partners. INCORPORATED in Delaware in 1984. OFFICE- 180 Varick St., New York, NY, USA 10014 (Tel.: 212-645-1405). Fax - 212-645-2054. WEBSITE-http://www.imclone.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.